A ubiquitous chromatin opening element prevents transgene silencing in pluripotent stem cells and their differentiated progeny

Stem Cells

Volumn 31, Issue 3, 2013, Pages 488-499

  Pfaff, Nils ^a   Lachmann, Nico ^a   Ackermann, Mania ^a   Kohlscheen, Saskia ^a   Brendel, Christian ^b   Maetzig, Tobias ^a   Niemann, Heiner ^a,c   Antoniou, Michael N ^d   Grez, Manuel ^b   Schambach, Axel ^a   Cantz, Tobias ^a   Moritz, Thomas ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Institute for Biomedical Research   (Germany)

^c FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Hematopoiesis; Induced pluripotent stem cells; Transgene silencing; Ubiquitous chromatin opening element

Indexed keywords

CYTARABINE; CYTIDINE DEAMINASE; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CHROMATIN; CONTROLLED STUDY; EMBRYONIC STEM CELL; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MOUSE; NONHUMAN; PLURIPOTENT STEM CELL; PROGENY; PROTEIN EXPRESSION; SPLEEN FOCUS FORMING VIRUS; TRANSGENE; UBIQUITOUS CHROMATIN OPENING ELEMENT; WESTERN BLOTTING;

ANIMALS; CELL DIFFERENTIATION; CHROMATIN; GENE SILENCING; GENETIC VECTORS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICE; TRANSGENES;

EID: 84874870904     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1316     Document Type: Article

References (51)

1. Wu SM, Hochedlinger K. Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat Cell Biol 2011;13: 497-505.
2. Sancho-Martinez I, Li M, Izpisua Belmonte JC. Disease correction the iPSC way: Advances in iPSC-based therapy. Clin Pharmacol Ther 2011;89: 746-749.
3. Ellis J. Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther 2005;16: 1241-1246.
4. Niwa O, Yokota Y, Ishida H et al. Independent mechanisms involved in suppression of the Moloney leukemia virus genome during differentiation of murine teratocarcinoma cells. Cell 1983;32: 1105-1113.
5. Stewart CL, Stuhlmann H, Jahner D et al. De novo methylation, expression, and infectivity of retroviral genomes introduced into embryonal carcinoma cells. Proc Natl Acad Sci USA 1982;79: 4098-4102.
6. Raya A, Rodriguez-Piza I, Guenechea G et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009;460: 53-59.
7. Wu G, Liu N, Rittelmeyer I et al. Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells. PLoS Biol 2011;9:e1001099.
8. Herbst F, Ball CR, Tuorto F et al. Extensive methylation of promoter sequences silences lentiviral transgene expression during stem cell differentiation in vivo. Mol Ther 2012;20: 1014-1021.
9. Challita PM, Kohn DB. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc Natl Acad Sci USA 1994;91: 2567-2571.
10. Klug CA, Cheshier S, Weissman IL. Inactivation of a GFP retrovirus occurs at multiple levels in long-term repopulating stem cells and their differentiated progeny. Blood 2000;96: 894-901.
11. Mukherjee S, Santilli G, Blundell MP et al. Generation of functional neutrophils from a mouse model of X-linked chronic granulomatous disorder using induced pluripotent stem cells. PLoS One 2011;6: e17565.
12. Zou J, Sweeney CL, Chou BK et al. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: Functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood 2011;117: 5561-5572.
13. Antoniou M, Harland L, Mustoe T et al. Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencing. Genomics 2003;82: 269-279.
14. Harland L, Crombie R, Anson S et al. Transcriptional regulation of the human TATA binding protein gene. Genomics 2002;79: 479-482.
15. Zhang F, Thornhill SI, Howe SJ et al. Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood 2007;110: 1448-1457.
16. Williams S, Mustoe T, Mulcahy T et al. CpG-island fragments from the HNRPA2B1/CBX3 genomic locus reduce silencing and enhance transgene expression from the hCMV promoter/enhancer in mammalian cells. BMC Biotechnol 2005;5: 17.
17. Zhang F, Frost AR, Blundell MP et al. A ubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors. Mol Ther 2010;18: 1640-1649.
18. Brendel C, Muller-Kuller U, Schultze-Strasser S et al. Physiological regulation of transgene expression by a lentiviral vector containing the A2UCOE linked to a myeloid promoter. Gene Ther 2012;19: 1018-1029.
19. Moritz T, Williams DA. Marrow protection - Transduction of hematopoietic cells with drug resistance genes. Cytotherapy 2001;3: 67-84.
20. Flasshove M, Moritz T, Bardenheuer W et al. Hematoprotection by transfer of drug-resistance genes. Acta Haematol 2003;110: 93-106.
21. Bardenheuer W, Lehmberg K, Rattmann I et al. Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells. Leukemia 2005;19: 2281-2288.
22. Momparler RL, Eliopoulos N, Bovenzi V et al. Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells. Cancer Gene Ther 1996;3: 331-338.
23. Neff T, Blau CA. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol 1996; 24: 1340-1346.
24. Rattmann I, Kleff V, Sorg UR et al. Gene transfer of cytidine deaminase protects myelopoiesis from cytidine analogs in an in vivo murine transplant model. Blood 2006;108: 2965-2971.
25. Brennig S, Rattmann I, Lachmann N et al. In vivo enrichment of cytidine deaminase gene-modified hematopoietic cells by prolonged cytosine- arabinoside application. Cytotherapy 2012;14: 451-460.
26. Lachmann N, Brennig S, Pfaff N et al. Efficient in vivo regulation of cytidine deaminase expression in the haematopoietic system using a doxycycline-inducible lentiviral vector system. Gene Ther 2012, doi: 10.1038/gt.2012.40 [Epub ahead of print, in press].
27. Baum C, Itoh K, Meyer J et al. The potent enhancer activity of the polycythemic strain of spleen focus-forming virus in hematopoietic cells is governed by a binding site for Sp1 in the upstream control region and by a unique enhancer core motif, creating an exclusive target for PEBP/CBF. J Virol 1997;71: 6323-6331.
28. Milsom MD, Jerabek-Willemsen M, Harris CE et al. Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells. Cancer Res 2008;68: 6171-6180.
29. Schambach A, Bohne J, Baum C et al. Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Ther 2006;13: 641-645.
30. Dull T, Zufferey R, Kelly M et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998;72: 8463-8471.
31. Pfaff N, Lachmann N, Kohlscheen S et al. Efficient hematopoietic redifferentiation of induced pluripotent stem cells derived from primitive murine bone marrow cells. Stem Cells Dev 2011;21: 689-701.
32. Gonzalez F, Barragan Monasterio M, Tiscornia G et al. Generation of mouse-induced pluripotent stem cells by transient expression of a single nonviral polycistronic vector. Proc Natl Acad Sci USA 2009;106: 8918-8922.
33. Lachmann N, Jagielska J, Heckl D et al. MicroRNA-150-regulated vectors allow lymphocyte-sparing transgene expression in hematopoietic gene therapy. Gene Ther 2012;19: 915-924.
34. Bock C, Reither S, Mikeska T et al. BiQ Analyzer: Visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics 2005;21: 4067-4068.
35. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
36. Szabo PE, Hubner K, Scholer H et al. Allele-specific expression of imprinted genes in mouse migratory primordial germ cells. Mech Dev 2002;115: 157-160.
37. Wiles MV, Keller G. Multiple hematopoietic lineages develop from embryonic stem (ES) cells in culture. Development 1991;111: 259-267.
38. Reubinoff BE, Pera MF, Fong CY et al. Embryonic stem cell lines from human blastocysts: Somatic differentiation in vitro. Nat Biotechnol 2000;18: 399-404.
39. Lindahl Allen M, Antoniou M. Correlation of DNA methylation with histone modifications across the HNRPA2B1-CBX3 ubiquitously-acting chromatin open element (UCOE). Epigenetics 2007;2: 227-236.
40. Ott MG, Schmidt M, Schwarzwaelder K et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006;12: 401-409.
41. Stein S, Ott MG, Schultze-Strasser S et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010;16: 198-204.
42. Knight S, Zhang F, Mueller-Kuller U et al. Safer, silencing-resistant lentiviral vectors: Optimization of the ubiquitous chromatin-opening element through elimination of aberrant splicing. J Virol 2012;86: 9088-9095.
43. Hockemeyer D, Soldner F, Beard C et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol 2009;27: 851-857.
44. Mussolino C, Cathomen T. On target? Tracing zinc-finger-nuclease specificity. Nat Methods 2011;8: 725-726.
45. Cermak T, Doyle EL, Christian M et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res 2011;39:e82.
46. Turan S, Bode J. Site-specific recombinases: From tag-and-target- to tag-and-exchange-based genomic modifications. FASEB J 2011;25: 4088-4107.
47. Turan S, Galla M, Ernst E et al. Recombinase-mediated cassette exchange (RMCE): Traditional concepts and current challenges. J Mol Biol 2011;407: 193-221.
48. Burt RK, Verda L, Kim DA et al. Embryonic stem cells as an alternate marrow donor source: Engraftment without graft-versus-host disease. J Exp Med 2004;199: 895-904.
49. Choi KD, Yu J, Smuga-Otto K et al. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells 2009;27: 559-567.
50. Ma F, Ebihara Y, Umeda K et al. Generation of functional erythrocytes from human embryonic stem cell-derived definitive hematopoiesis. Proc Natl Acad Sci USA 2008;105: 13087-13092.
51. Vodyanik MA, Bork JA, Thomson JA et al. Human embryonic stem cell-derived CD34+ cells: Efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential. Blood 2005;105: 617-626.